Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer
NCT02524951Phase 1Terminated
- Sponsor
- Northwell Health
- Start
- Apr 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trodusquemine in breast cancer (7 arms), sponsored by Northwell Health. Primary endpoint: Maximally Tolerated Dose at 1 year. Started Apr 2016; status: terminated.
02
Drugs
trodusquemine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02524951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524951.